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Objectives: This study aimed to analyse the in vitro activity of dual combinations of carbapenems against
Klebsiella pneumoniae producing the main carbapenemase types.
Methods:MIC values of the carbapenems, imipenem, meropenem, ertapenem and doripenemwere determined
alone and in dual combinations for 20 clinical K. pneumoniae isolates producing representative carbapenemases,
i.e. OXA-48 (n¼6), NDM-1 (n¼4), NDM-1+OXA-48 (n¼2) and KPC-2 (n¼8). MICs were also determined for
Escherichia coli recombinant strains with or without permeability defects producing NDM-1, OXA-48 or KPC-2.
In vitro synergy combination testing was performed using the microdilution and chequerboard techniques.
Fractional inhibitory concentration indexes were calculated to determine whether the combinations were syner-
gistic, indifferent or antagonistic.
Results: All carbapenemase producers were resistant to the tested carbapenems, with most isolates showing
MICs of carbapenems .32 mg/L. None of the combinations was antagonistic. For KPC producers, synergistic
combinations were observed with imipenem/ertapenem (5/8 isolates), imipenem/doripenem (4/8), imipenem/
doripenem (4/8), meropenem/doripenem (3/8) and ertapenem/doripenem (3/8), while no synergy was observed
with meropenem/ertapenem. For OXA-48 producers, synergies were observed with imipenem/ertapenem and
with imipenem/meropenem for both isolates tested. Notably, combining imipenem with a non-carbapenem
b-lactam (cefalotin) did not give any synergistic result. No synergy was observed for all NDM-1 and NDM-
1+OXA-48 producers. Time–kill assays conﬁrmed most of the data obtained by chequerboard testing.
Conclusions: The data strongly support the hypothesis that dual carbapenem combinations might be effective
against serine-b-lactamase producers (KPC, OXA-48). The imipenem-containing combinations appeared to be
the most efﬁcient.
Introduction
MDR Enterobacteriaceae are increasingly reported and currently
represent one of the main threats to public health.1 Among the
MDR bacteria, emergence of Klebsiella pneumoniae isolates resist-
ant to carbapenems is of particular importance, since they are
mostly the source of nosocomial infections in severely ill patients.2
Resistance to carbapenems in K. pneumoniae is mainly due to the
production of carbapenem-hydrolysing b-lactamases such as the
KPC type (Ambler class A), IMP, VIM and NDM types (class B) and
OXA-48 (class D).3 KPC producers are mainly identiﬁed in the USA,
South America, Greece and Italy,4 VIM producersmainly in Greece
and Italy5 and IMP producers in Japan and Australia.3 NDM produ-
cers have been identiﬁed mainly from India, Pakistan, Bangladesh,
theMiddle East and the UK, and subsequently frommany countries
worldwide, but often with a link with the Indian subcontinent.6
Finally, OXA-48 producers are mainly reported in Europe (France,
Belgium, Spain), Turkey and North African countries.7 Most of the
carbapenemase producers are resistant to all b-lactams, including
carbapenems, to most aminoglycosides, and to ﬂuoroquinolones,
fosfomycin and sulphonamides, remaining mostly susceptible to
very few antibiotics (tigecycline and colistin).
Antibiotic combination schemes including a carbapenem and
colistin, tigecycline, fosfomycin or an aminoglycoside might be
efﬁcient against carbapenemase-producing K. pneumoniae, with
combination therapies being proved to be more efﬁcient than
monotherapies.8
However, colistin and tigecycline raise some concern about
toxicity and poor diffusion in the urinary tract, respectively.
Furthermore, frequent colistin usemay select for colistin resistance,
as exempliﬁed by the current situation with KPC producers in Italy.9
Therefore, pioneer studies performed using animal models of
infections or experimental treatments of patients have suggested
the use of carbapenem combinations for treating infections
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caused by carbapenemase producers. The rationale of combin-
ing carbapenems (and in particular ertapenem with another
carbapenem) would be that ertapenem may bind to the active
site of the carbapenemase with high afﬁnity, and therefore may
prevent the hydrolysis of the other carbapenem molecule, this
drug combination presumably being more effective.10,11 The
mode of action of these kinds of combinations would be some-
what similar to that of amoxicillin and the b-lactamase inhibitor
clavulanic acid, for example.
Therefore our objective was to analyse in vitro the activity
of dual carbapenem combinations against different types of
carbapenemase-producing K. pneumoniae.
Materials and methods
A collection of 20 clonally unrelated carbapenemase-producing K. pneu-
moniae isolates was included in the study. They produced the three
main types of carbapenemases: KPC-2 (n¼8), NDM-1 (n¼4) and
OXA-48 (n¼6). Two isolates co-produced two carbapenemases, i.e.
NDM-1 and OXA-48. These isolates were of worldwide origin (India, USA,
Canada, Colombia, France, Israel, Turkey, Sultanate of Oman, Kuwait and
Morocco), have been previously fully characterized for their b-lactamase
content and have been selected for their resistance to carbapenems
(Table 1). In addition, each carbapenemase gene was separately cloned
into the same plasmid pCRw-Blunt II-TOPOw (Invitrogen, Illkirch, France)
and expressed in two recipient strains: Escherichia coli TOP10 (WT) and
E. coli HB4 (exhibiting permeability defects since it lacks porins OmpC
and OmpF12).13 The MICs for all the isolates of cefalotin and the four
carbapenems, namely doripenem, ertapenem, imipenem and merope-
nem, were determined by using the broth microdilution technique as
recommended by the CLSI guidelines.14 Carbapenem breakpoints estab-
lished by the CLSI for Enterobacteriaceae are as follows: doripenem,
≤1/≥4 mg/L; ertapenem, ≤0.5/≥2 mg/L; imipenem, ≤1/≥4 mg/L; and
meropenem, ≤1/≥4 mg/L. Chequerboard synergy testing was performed
as described previously15,16 using combinations of two carbapenems or a
combination of cefalotin and imipenem as a control. Chequerboard syn-
ergy testing was performed in duplicate with the 20 carbapenemase-
producing K. pneumoniae isolates, and in addition with the 3 E. coli
TOP10 and the 3 E. coli HB4 recombinant strains. Fractional inhibitory con-
centration (FICs) indexes were calculated according to the formula
SFIC¼FIC of drug A+FIC of drug B, where FIC of drug A or B¼MIC of
drug A or B in combination divided by the MIC of drug A or B alone.
Table 1. Features of clinical isolates and recombinant strains
Isolates Country of isolation Carbapenemases
MICs (mg/L)
Associated b-lactamasesIPM MEM DOR ETP
K. pneumoniae clinical isolates
K301 Colombia KPC-2 .512 1024 512 .1024 SHV-11
K315 France KPC-2 512 64 32 128 SHV-11
K23 Colombia KPC-2 256 512 256 512 SHV-11
K322 France KPC-2 128 128 32 256 SHV-12
K317 France KPC-2 128 128 32 128 SHV-12+OXA-9
K302 Israel KPC-2 64 64 32 128 SHV-11+TEM-1+OXA-9
HMA284 Canada KPC-3 64 64 16 128 none
YC USA KPC-2 32 64 16 128 SHV-11+SHV-12+TEM-1+OXA-9
BIC France OXA-48 64 64 32 256 none
11978 Turkey OXA-48 64 32 32 128 SHV-2a+SHV-11+OXA-47+TEM-1+OXA-1
52 France OXA-48 16 32 8 64 ND
43 France OXA-48 16 4 4 8 ND
E212 France OXA-48 8 32 16 256 ND
ALI Kuwait OXA-48 8 16 4 8 SHV-28
4N14 France NDM-1 128 128 128 64 SHV-11+TEM-1+CTX-M-15+OXA-1+OXA-9
OMA2 Oman NDM-1 16 64 64 128 SHV-11+OXA-1
NAS France NDM-1 64 64 32 128 CTX-M-15+TEM-1+SHV-11+OXA-1
6560 Morocco NDM-1 16 32 32 64 CTX-M-15+TEM-1+SHV-5+OXA-1+OXA-9
T45 Turkey NDM-1+OXA-181 512 512 256 512 ND
C93 Turkey NDM-1+OXA-181 512 512 256 512 ND
Recombinant E. coli
clone 1 KPC-2 128 32 16 32 none
clone 2 OXA-48 1024 256 128 1024 none
clone 3 NDM-1 64 32 16 32 none
clone 1b KPC-2 16 16 8 16 none
clone 2b OXA-48 4 1 1 2 none
clone 3b NDM-1 8 8 4 8 none
IPM, imipenem; MEM, meropenem; DOR, doripenem; ETP, ertapenem; ND, not determined.
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Interpretation of the results was based on the following: FICvalues of≤0.5
indicate synergy, FIC values of .0.5 to 4 indicate no interaction and FIC
values of .4 indicate antagonism.17
Time–kill assays were performed as described previously.18,19 Killing
effects were quantiﬁed by standard time–kill assays using effective carba-
penem concentrations as suggested by chequerboard experimental data
(Table 2). Log kill was determined bymicrodilution on MH agar after 2, 4, 6,
9 and 10 h of incubation with carbapenems alone or in combination.
Synergies were considered when a log10 kill difference of≥2 was observed
for carbapenem combinations compared with single carbapenem treat-
ments at a given timepoint. Corresponding data are summarized in
Table 2.
Results
Determination of MICs of carbapenems for the 20 carbapenemase
producers showed that all isolates were resistant to doripenem
(MICs ranging from 4 to 256 mg/L), ertapenem (8 to .1024 mg/L),
imipenem (8 to .512 mg/L) and meropenem (4–1024 mg/L). The
two isolates co-producing NDM-1+OXA-48 showed very high MICs
of all carbapenems (Table 1). The E. coli HB4 recombinant strains
were highly resistant to all carbapenems, whereas E. coli TOP10
showed lower MICs, as expected (Table 1). All strains were resistant
to cefalotin.
Interestingly, in vitro synergistic activity was noticed with the
combinations imipenem/meropenem (n¼8 isolates), imipenem/
ertapenem (n¼8), imipenem/doripenem (n¼4), doripenem/
meropenem (n¼3) and doripenem/ertapenem (n¼3), but not
with the ertapenem/meropenem combination (Table 1). At least
one synergistic combination was systematically observed with
all KPC producers, whereas it was obtained for only four out of
the six OXA-48 producers. No synergy was found for all combina-
tions of all NDM-1 producers, including those co-producing
OXA-48. Overall, our results showed that many combinations
resulted in mainly no interaction (Table 1). However, no antagon-
ism (deﬁned by an FIC .4) was noticed with any of the six com-
binations tested.
When analysing the distribution of signiﬁcant synergies
obtained during this duplicate experiment, the best results were
obtained with all combinations including imipenem either for
KPC and OXA-48 producers, and also with the ertapenem/dori-
penem combination, but only for the KPC producers.
In order to evaluate whether the dual carbapenem synergy
observed with KPC or OXA-48 producers might be attributed to
the type of carbapenemase produced or rather to the speciﬁc
genetic background of the host strain, a comparative evaluation
was conducted with different E. coli isogenic backgrounds (either
exhibiting aWTsusceptibility pattern or permeability defects) pro-
ducing the carbapenemase KPC-2, OXA-48 or NDM-1. Accordingly,
E. coli TOP10 and E. coli HB4 recombinant strains were respectively
supposed to exhibit low and high MICs of carbapenems (Table 1).
Synergistic activities were identiﬁed only against the KPC-2 produ-
cer, whereas no synergy was found against either OXA-48 or
NDM-1. Three out of the six combinations tested (imipenem/
meropenem, imipenem/ertapenem and imipenem/doripenem)
were found to be synergistic against the KPC-2-producing strain
when E. coli HB4 was used as background, and only one (imipe-
nem/doripenem) when E. coli TOP10 was used as background.
It was noteworthy that all of the combinations showing syner-
gistic activity included imipenem. In order to evaluate whether
the synergies observed could indeed be attributed to the dual car-
bapenem combination, and not to imipenem only, the imipenem/
cefalotin combination was also tested in isolates for which syner-
gies had been observed with combinations including imipenem,
but no synergistic effect was observed.
Time–kill assays conﬁrmed many of the synergies evidenced
by the chequerboard assays. This was particularly true for imipe-
nem/doripenem and ertapenem/doripenem (Table 2). The syner-
gies obtained through time–kill assays were very signiﬁcant for
some speciﬁc combinations, as exempliﬁed with the meropenem/
doripenem combination against a KPC-2-producing strain and the
imipenem/ertapenem combination against an OXA-48-producing
strain (Figure 1).
Discussion
This study showed that dual combinations of carbapenems
might be synergistic against carbapenem-resistant and
carbapenemase-producing K. pneumoniae isolates. We found evi-
dence that the efﬁcacy of the dual carbapenem combinations
depended on the type of combination, those including imipenem
or doripenem being themost efﬁcient. These results disagreewith
the hypothesis that ertapenem might be the carbapenem mol-
ecule of choice to partially inactivate the carbapenemase activity.
Synergies were frequently obtained with KPC producers, and to a
lesser extent with OXA-48 producers (both enzymes being serine
b-lactamases), but not with NDM (a metallo-b-lactamase) pro-
ducers. We showed that synergies were more likely to occur
with clinical isolates showing high rather than moderate MICs of
carbapenems.
Overall, our results agree with the observations made by
Giamarellou et al.,20 who noticed a successful outcome (and
presumably synergistic activity) of the doripenem/ertapenem
combination when treating a single patient infected with a
KPC-2-producing K. pneumoniae, and with Ceccarelli et al.,21
who reported the clinical success of the same combination
against a KPC-3-producing K. pneumoniae. Our results are also
consistent with those published by Bulik and Nicolau,22 who
demonstrated in a chemostat and in an in vivomurine thigh infec-
tion model that the doripenem/ertapenem combination had
enhanced efﬁcacy compared with either agent alone. By contrast,
our results do not conﬁrm the time–kill study performed by Oliva
et al.,23 who showed that synergistic activity might be obtained
in vitro with ertapenem/meropenem against KPC-producing
K. pneumoniae, since no synergistic activity was noted here for
any of the isolates tested with that combination.
The results of the present study justify additional in vivo
investigations. In view of our results, an imipenem-containing
dual carbapenem therapy may be efﬁcient, in the context of
treating an infection caused by a carbapenem-resistant and
carbapenemase-producing K. pneumoniae. It remains to be
determined whether the dual carbapenem combinations are
more efﬁcient than combinations of a carbapenem and a
non-b-lactam molecule, such as colistin, fosfomycin or tigecyc-
line.24 However, since replacement of one of the carbapenems
by a cephalosporin negatively interferes with the synergistic
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Table 2. MICs, FIC variations and chequerboard synergy testing for carbapenemase-producing isolates
Isolates Carbapenemases
FIC variations Chequerboard synergy testinga
Concentrations of
carbapenems (mg/L)b
IPM+MEM IPM+ETP DOR+IPM MEM+DOR ETP+DOR ETP+MEM IPM+MEM IPM+ETP DOR+IPM MEM+DOR ETP+DOR ETP+MEM IPM MEM DOR ETP
K. pneumoniae clinical isolates
K301 KPC-2 0.75–0.75 0.5–0.5 0.63–0.63 0.75–0.75 0.63–0.63 0.63–0.63 NI/NI SYN/SYN NI/NI NI/NI NI/NI NI/NI 256 / / 512
K315 KPC-2 0.53–0.56 0.5–0.5 0.5–0.5 0.75–0.75 0.75–0.75 0.75–0.75 NI/NI SYN/SYN SYN/SYN NI/NI NI/NI NI/NI 2c / 1c 8c
K23 KPC-2 0.38–0.38 0.38–0.38 0.38–0.38 0.5–0.62 0.75–0.75 0.75–0.75 SYN/SYN SYN/SYN SYN/SYN SYN/NI NI/NI NI/NI 32 128 64 128
K322 KPC-2 0.5–0.5 0.51–0.53 0.56–0.56 0.5–0.5 0.75–0.75 1–1 SYN/SYN NI/NI NI/NI SYN/SYN NI/NI NI/NI 4c 4c 2c /
K317 KPC-2 0.75–0.75 0.5–0.5 0.63–0.63 0.63–0.63 0.31–0.38 1–0.75 NI/NI SYN/SYN NI/NI NI/NI SYN/SYN NI/NI 4c / 2c 4c
K302 KPC-2 0.5–0.38 0.38–0.56 0.5–0.38 0.63–0.5 0.5–0.38 0.53–0.56 SYN/SYN SYN/NI SYN/SYN NI/SYN SYN/SYN NI/NI 8c 4c 4c 8c
HMA284 KPC-3 0.53–0.56 0.56–0.56 0.75–0.75 0.75–0.75 0.5–0.5 0.63–0.63 NI/NI NI/NI NI/NI NI/NI SYN/SYN NI/NI / / 2c 8c
YC KPC-2 0.5–1 0.53–0.56 0.38–0.5 1–0.75 0.75–0.75 1–0.75 SYN/NI NI/NI SYN/SYN NI/NI NI/NI NI/NI 2c 8c 2c /
BIC OXA-48 0.5–0.63 0.63–0.5 0.75–0.56 1–0.63 0.75–0.75 0.75–0.56 SYN/NI NI/SYN NI/NI NI/NI NI/NI NI/NI 1c 1c / 2c
11978 OXA-48 1–0.5 0.75–0.63 0.56–0.51 0.63–0.63 0.75–0.75 0.75–0.75 NI/SYN NI/NI NI/NI NI/NI NI/NI NI/NI 16 16 / /
52 OXA-48 0.5–0.75 0.63–0.5 1–1 0.56–0.56 0.75–0.75 0.53–0.56 SYN/NI NI/SYN NI/NI NI/NI NI/NI NI/NI 1c 4c / 16
43 OXA-48 0.53–0.53 0.52–0.52 0.56–0.56 0.75–0.75 0.53–0.56 0.63–0.63 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
E212 OXA-48 1–1 1.5–1.5 0.75–0.75 0.75–0.75 1–1 1–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
ALI OXA-48 0.5–0.5 0.5–0.5 0.75–0.75 0.75–1 1–0.75 0.75–1 SYN/SYN SYN/SYN NI/NI NI/NI NI/NI NI/NI 2c 1c / 2c
4N14 NDM-1 1–1 1–1 0.75–0.75 1–1 0.75–0.75 0.75–0.75 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
OMA2 NDM-1 1–0.63 0.75–0.75 0.75–0.63 0.56–0.56 0.63–0.56 0.75–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
NAS NDM-1 0.75–0.75 0.75–0.63 1.5–1 1–0.75 0.75–1 1–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
6560 NDM-1 0.56–0.63 0.63–0.63 0.75–0.75 1–0.75 1–1 0.75–0.75 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
T45 NDM-1+OXA-181 0.63–1 0.75–0.75 0.63–0.75 1–1 1–1 1–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
C93 NDM-1+OXA-181 0.75–0.75 0.63–1 1–1 1–1 0.75–0.75 1–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
Recombinant E. coli
clone 1 KPC-2 0.63–0.5 0.63–0.5 0.5–0.31 0.75–0.75 0.63–0.63 1–1 NI/SYN NI/SYN SYN/SYN NI/NI NI/NI NI/NI 8c 4c 4c 8c
clone 2 OXA-48 1–0.75 0.75–0.63 1–1 0.63–0.63 0.56–0.53 0.75–0.75 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
clone 3 NDM-1 0.75–0.75 1.0–1.0 0.75–0.75 0.75–1 0.75–0.75 1–1 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
clone 1b KPC-2 0.75–0.75 0.75–0.75 0.5–0.5 0.75–0.75 0.75–1 0.75–0.75 NI/NI NI/NI SYN/SYN NI/NI NI/NI NI/NI 4c / 2c /
clone 2b OXA-48 1–1 0.75–0.75 0.75–1 1–1 1–0.75 0.75–0.75 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
clone 3b NDM-1 1–1 1–1 0.75–1 1–0.75 1–1 0.75–0.75 NI/NI NI/NI NI/NI NI/NI NI/NI NI/NI / / / /
IPM, imipenem; MEM, meropenem; DOR, doripenem; ETP, ertapenem; SYN, synergy; NI, no interaction.
Dark grey shading, conﬁrmed by time–kill assay; light grey shading, not conﬁrmed.
aResults represent interpretations of theminimum andmaximum FIC values; two separate experiments were performed, hence the two results obtained (shown separated with a slash).
bConcentrations for which the synergy was obtained by using chequerboard analyses.
cValues that are compatible with the clinically utilized doses.
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effect, this suggests that such an effect can be obtained only with
two carbapenem molecules.
We might ultimately consider also that a triple combination
with two synergistic carbapenems and another non-b-lactam
antibiotic would be an efﬁcient alternative. This kind of strategy
might be thus evaluated at least in vitro.
Regarding the OXA-48 producers, successful synergies were
observed for some clinical K. pneumoniae isolates, but not with
recombinant E. coli strains. However, it must be noted that the
FIC values of the imipenem-based combinations obtained for
either the clinical isolates or the recombinant strains were not
very different, being close to the cut-off value, which is 0.5 for
deﬁning synergy. Therefore, we cannot rule out that slight synergy
may exist against OXA-48, but not as efﬁcient as against the KPC
producers.
It remains intriguing why none of the dual combinations was
synergistic against NDM-1 producers. This might be related to
the mechanism of action of metallo-b-lactamases, which differs
signiﬁcantly from that of serine-based carbapenemases.25
Treatment of infections caused by metallo-b-lactamase produ-
cers may therefore remain particularly challenging since even
the b-lactam/b-lactamase inhibitor combination ceftazidime/avi-
bactam is not efﬁcient in these cases. Overall, our study provides
additional knowledge on potential treatment strategies aimed at
eradicating MDR strains. As recently highlighted by Thomson,26
knowledge regarding double-carbapenem therapies must be
extended and we believe this present study will signiﬁcantly
contribute to this goal.
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